Jou YS - Search Results

1

Xist reduction in breast cancer upregulates AKT phosphorylation via HDAC3-mediated repression of PHLPP1 expression.

Huang YS, Chang CC, Lee SS, Jou YS, Shih HM. Huang YS, et al. Among authors: jou ys. Oncotarget. 2016 Jul 12;7(28):43256-43266. doi: 10.18632/oncotarget.9673. Oncotarget. 2016. PMID: 27248326 Free PMC article.

2

Inhibition of gap junctional intercellular communication and malignant transformation of rat liver epithelial cells by neu oncogene.

Jou YS, Layhe B, Matesic DF, Chang CC, de Feijter AW, Lockwood L, Welsch CW, Klaunig JE, Trosko JE. Jou YS, et al. Carcinogenesis. 1995 Feb;16(2):311-7. doi: 10.1093/carcin/16.2.311. Carcinogenesis. 1995. PMID: 7859363

3

Etk, a Btk family tyrosine kinase, mediates cellular transformation by linking Src to STAT3 activation.

Tsai YT, Su YH, Fang SS, Huang TN, Qiu Y, Jou YS, Shih HM, Kung HJ, Chen RH. Tsai YT, et al. Among authors: jou ys. Mol Cell Biol. 2000 Mar;20(6):2043-54. doi: 10.1128/MCB.20.6.2043-2054.2000. Mol Cell Biol. 2000. PMID: 10688651 Free PMC article.

4

YY1AP, a novel co-activator of YY1.

Wang CY, Liang YJ, Lin YS, Shih HM, Jou YS, Yu WC. Wang CY, et al. Among authors: jou ys. J Biol Chem. 2004 Apr 23;279(17):17750-5. doi: 10.1074/jbc.M310532200. Epub 2004 Jan 26. J Biol Chem. 2004. PMID: 14744866 Free article.

5

A Cullin3-KLHL20 Ubiquitin ligase-dependent pathway targets PML to potentiate HIF-1 signaling and prostate cancer progression.

Yuan WC, Lee YR, Huang SF, Lin YM, Chen TY, Chung HC, Tsai CH, Chen HY, Chiang CT, Lai CK, Lu LT, Chen CH, Gu DL, Pu YS, Jou YS, Lu KP, Hsiao PW, Shih HM, Chen RH. Yuan WC, et al. Among authors: jou ys. Cancer Cell. 2011 Aug 16;20(2):214-28. doi: 10.1016/j.ccr.2011.07.008. Cancer Cell. 2011. PMID: 21840486 Free article.

6

SPANXA suppresses EMT by inhibiting c-JUN/SNAI2 signaling in lung adenocarcinoma.

Hsiao YJ, Su KY, Hsu YC, Chang GC, Chen JS, Chen HY, Hong QS, Hsu SC, Kang PH, Hsu CY, Ho BC, Yang TH, Wang CY, Jou YS, Yang PC, Yu SL. Hsiao YJ, et al. Among authors: jou ys. Oncotarget. 2016 Jul 12;7(28):44417-44429. doi: 10.18632/oncotarget.10088. Oncotarget. 2016. PMID: 27323831 Free PMC article.

7

FNDC3B promotes cell migration and tumor metastasis in hepatocellular carcinoma.

Lin CH, Lin YW, Chen YC, Liao CC, Jou YS, Hsu MT, Chen CF. Lin CH, et al. Among authors: jou ys. Oncotarget. 2016 Aug 2;7(31):49498-49508. doi: 10.18632/oncotarget.10374. Oncotarget. 2016. PMID: 27385217 Free PMC article.

8

Pyrimidine metabolic rate limiting enzymes in poorly-differentiated hepatocellular carcinoma are signature genes of cancer stemness and associated with poor prognosis.

Yeh HW, Lee SS, Chang CY, Hu CM, Jou YS. Yeh HW, et al. Among authors: jou ys. Oncotarget. 2017 Sep 8;8(44):77734-77751. doi: 10.18632/oncotarget.20774. eCollection 2017 Sep 29. Oncotarget. 2017. PMID: 29100421 Free PMC article.

9

EIF3C-enhanced exosome secretion promotes angiogenesis and tumorigenesis of human hepatocellular carcinoma.

Lee HY, Chen CK, Ho CM, Lee SS, Chang CY, Chen KJ, Jou YS. Lee HY, et al. Among authors: jou ys. Oncotarget. 2018 Jan 11;9(17):13193-13205. doi: 10.18632/oncotarget.24149. eCollection 2018 Mar 2. Oncotarget. 2018. PMID: 29568350 Free PMC article.

10

PSPC1 mediates TGF-β1 autocrine signalling and Smad2/3 target switching to promote EMT, stemness and metastasis.

Yeh HW, Hsu EC, Lee SS, Lang YD, Lin YC, Chang CY, Lee SY, Gu DL, Shih JH, Ho CM, Chen CF, Chen CT, Tu PH, Cheng CF, Chen RH, Yang RB, Jou YS. Yeh HW, et al. Among authors: jou ys. Nat Cell Biol. 2018 Apr;20(4):479-491. doi: 10.1038/s41556-018-0062-y. Epub 2018 Mar 28. Nat Cell Biol. 2018. PMID: 29593326

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

89 results

Search Page